1. PDS Biotech Accelerates Regulatory Path for Key Cancer Immunotherapy After Protocol Change
PDS Biotech has signaled a faster route to market for its lead candidate, PDS0101, following a strategic amendment to its pivotal VERSATILE-003 trial protocol. The company now projects a potential Biologics License Application (BLA) submission in the first half of 2025, a timeline accelerated from prior expectations. T...